EUVIMEDEUVIMED entdecken
Open Access

Association Between Proton Pump Inhibitor Use and Malnutrition Risk in the US General Population Using the GLIM Framework ( NHANES 1999–2020)

Zusammenhang zwischen Protonenpumpeninhibitor-Anwendung und Malnutritionsrisiko in der US-Allgemeinbevölkerung mit dem GLIM-Rahmenwerk (NHANES 1999–2020)

F Orsini iD, A Novella, L Pasina iD

Pharmacoepidemiology and Drug Safety · 2026-09 · 35 (9)

DOI: 10.1002/pds.70451 ↗

Auf einen Blick

In einer Querschnittsanalyse war die Anwendung von Protonenpumpeninhibitoren mit einem höheren Malnutritionsrisiko verbunden. Das galt auch für schwere Malnutrition, besonders bei Frauen und bei Menschen ab 65 Jahren.

Fragestellung

Besteht in der US-Allgemeinbevölkerung ein unabhängiger Zusammenhang zwischen PPI-Anwendung und Malnutritionsrisiko nach GLIM-Kriterien?

Methode

Querschnittsanalyse von NHANES 1999–2020; GLIM-Kriterien; robuste Poisson-Regression für allgemeine Malnutrition, logistische Regression für schwere Malnutrition; Adjustierung für soziodemografische Faktoren, Food Security, Komorbiditäten und Medikamente.

Ergebnisse

23 363 Erwachsene. Prävalenz der Malnutrition: 18,9 % (95 %-KI 18,4 %–19,4 %). PPI-Anwendung: RR 1,10 (95 %-KI 1,01–1,19). Schwere Malnutrition: OR 1,36 (95 %-KI 1,13–1,63). Frauen: RR 1,37 (95 %-KI 1,06–1,79). ≥ 65 Jahre: OR 1,57 (95 %-KI 1,15–2,14).

Schlussfolgerung der Autor:innen

Eine längere iatrogene Hypochlorhydrie könnte ein wichtiger Beitrag zur Malnutrition sein, besonders zu schwereren Formen und bei älteren Erwachsenen.

Kernaussagen

  • PPI-Anwendung war mit höherem Malnutritionsrisiko assoziiert.
  • Für schwere Malnutrition zeigte sich ein unabhängiger Zusammenhang.
  • Der Zusammenhang war bei Frauen und bei ≥ 65-Jährigen stärker.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 31.08.2026. Verfasst von F Orsini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmacology and Appropriateness of Drug Prescription, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Malnutrition. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proton pump inhibitors (PPIs) are the global gold standard for acid‐related disorders; however, their proliferation into long‐term, often non‐indicated use raises significant concerns regarding qualitative nutrient depletion.

Objective

This study primarily aimed to evaluate the independent association between PPI use and malnutrition risk according to the Global Leadership Initiative on Malnutrition (GLIM) criteria in a nationally representative US population.

Methods

We conducted a cross‐sectional analysis of 23 363 adults from the NHANES 1999–2020 database. Malnutrition was operationalized via the GLIM approach, integrating phenotypic criteria (weight loss, low BMI, or DXA‐derived reduced muscle mass) with etiologic criteria (inflammation or reduced calorie intake). Robust Poisson regression models estimated relative risks (RRs) for general malnutrition, while logistic regression estimated odds ratios (ORs) for severe malnutrition. Models were adjusted for sociodemographics, food security, comorbidities, and appetite‐affecting medications.

Results

The prevalence of malnutrition was 18.9% (95% CI: 18.4%–19.4%) and PPI use was associated with a 10% increased risk of malnutrition (RR 1.10; 95% CI: 1.01–1.19; p = 0.031) in the adjusted model. For severe malnutrition, PPI exposure was a robust independent predictor (OR 1.36; 95% CI: 1.13–1.63; p = 0.001). Notably, sex‐stratified analysis revealed a RR associated with PPIs was significantly more pronounced in females (RR 1.37; 95% CI: 1.06–1.79; p = 0.018) than in males (RR 1.07; p = 0.11). In the geriatric population (≥ 65 years), chronic PPI use increased the odds of severe malnutrition by 57% (OR 1.57; 95% CI: 1.15–2.14; p = 0.004).

Conclusion

Prolonged iatrogenic hypochlorhydria may represent an important contributor to malnutrition, particularly to its more severe forms and among older adults. These findings support the need for regular medication reviews to identify and discontinue unnecessary long‐term PPI therapy. Preserving metabolic and nutritional health may therefore require the implementation of non‐pharmacological approaches as first‐line management options for acid‐related disorders whenever clinically appropriate. Such strategies may help reduce unnecessary long‐term PPI exposure and its potential adverse effects on nutritional status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsMalnutritionHumansFemaleMaleCross-Sectional StudiesNutrition SurveysUnited StatesMiddle AgedAdultPrevalenceAgedRisk FactorsYoung Adult

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Laboratory of Clinical Pharmacology and Appropriateness of Drug Prescription, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Italian Institute for Planetary Health (IIPH), Milan, Italy.

ORCID-Profile: F Orsini, L Pasina

Zitieren

APA

Orsini, F., Novella, A., & Pasina, L. (2026). Association Between Proton Pump Inhibitor Use and Malnutrition Risk in the US General Population Using the GLIM Framework ( NHANES 1999–2020). Pharmacoepidemiology and Drug Safety, 35(9). https://doi.org/10.1002/pds.70451

Vancouver

Orsini F, Novella A, Pasina L. Association Between Proton Pump Inhibitor Use and Malnutrition Risk in the US General Population Using the GLIM Framework ( NHANES 1999–2020). Pharmacoepidemiology and Drug Safety. 2026;35(9). doi:10.1002/pds.70451

BibTeX
@article{Orsini2026,
  author = {Orsini, F and Novella, A and Pasina, L},
  title = {Association Between Proton Pump Inhibitor Use and Malnutrition Risk in the US General Population Using the GLIM Framework ( NHANES 1999–2020)},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  volume = {35},
  number = {9},
  doi = {10.1002/pds.70451}
}
Kostenlos starten →